409 related articles for article (PubMed ID: 31208307)
1. Accelerated Atherosclerosis in Rheumatoid Arthritis: Mechanisms and Treatment.
Reiss AB; Silverman A; Khalfan M; Vernice NA; Kasselman LJ; Carsons SE; De Leon J
Curr Pharm Des; 2019; 25(9):969-986. PubMed ID: 31208307
[TBL] [Abstract][Full Text] [Related]
2. Lipid profile of rheumatoid arthritis patients treated with anti-tumor necrosis factor-alpha drugs changes according to disease activity and predicts clinical response.
Cacciapaglia F; Anelli MG; Rinaldi A; Serafino L; Covelli M; Scioscia C; Iannone F; Lapadula G
Drug Dev Res; 2014 Nov; 75 Suppl 1():S77-80. PubMed ID: 25381986
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs.
Avouac J; Allanore Y
Expert Opin Pharmacother; 2008 May; 9(7):1121-8. PubMed ID: 18422470
[TBL] [Abstract][Full Text] [Related]
4. Impact of traditional therapies and biologics on cardiovascular diseases in rheumatoid arthritis.
Boyer JF; Cantagrel A; Constantin A
Curr Vasc Pharmacol; 2008 Jul; 6(3):218-27. PubMed ID: 18673161
[TBL] [Abstract][Full Text] [Related]
5. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis.
Roubille C; Richer V; Starnino T; McCourt C; McFarlane A; Fleming P; Siu S; Kraft J; Lynde C; Pope J; Gulliver W; Keeling S; Dutz J; Bessette L; Bissonnette R; Haraoui B
Ann Rheum Dis; 2015 Mar; 74(3):480-9. PubMed ID: 25561362
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular risk in rheumatoid arthritis: how to lower the risk?
van Breukelen-van der Stoep DF; Klop B; van Zeben D; Hazes JM; Castro Cabezas M
Atherosclerosis; 2013 Nov; 231(1):163-72. PubMed ID: 24125429
[TBL] [Abstract][Full Text] [Related]
7. Vascular effects of biologic agents in RA and spondyloarthropathies.
Szekanecz Z; Kerekes G; Soltész P
Nat Rev Rheumatol; 2009 Dec; 5(12):677-84. PubMed ID: 19901918
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular risk profile of antirheumatic agents in patients with osteoarthritis and rheumatoid arthritis.
Nurmohamed MT; van Halm VP; Dijkmans BA
Drugs; 2002; 62(11):1599-609. PubMed ID: 12109923
[TBL] [Abstract][Full Text] [Related]
9. Rheumatoid Arthritis Pharmacotherapies: Do They Have Anti-Atherosclerotic Activity?
Giles JT
Curr Rheumatol Rep; 2016 May; 18(5):27. PubMed ID: 27032790
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular Manifestations in Rheumatoid Arthritis.
Sanghavi N; Ingrassia JP; Korem S; Ash J; Pan S; Wasserman A
Cardiol Rev; 2024 Mar-Apr 01; 32(2):146-152. PubMed ID: 36729119
[TBL] [Abstract][Full Text] [Related]
11. What effects might anti-TNFalpha treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFalpha in cardiovascular pathophysiology.
Dixon WG; Symmons DP
Ann Rheum Dis; 2007 Sep; 66(9):1132-6. PubMed ID: 17251223
[TBL] [Abstract][Full Text] [Related]
12. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis.
Finckh A; Bansback N; Marra CA; Anis AH; Michaud K; Lubin S; White M; Sizto S; Liang MH
Ann Intern Med; 2009 Nov; 151(9):612-21. PubMed ID: 19884622
[TBL] [Abstract][Full Text] [Related]
13. Effects of anti-TNF-alpha treatment on lipid profile in patients with active rheumatoid arthritis.
Seriolo B; Paolino S; Sulli A; Fasciolo D; Cutolo M
Ann N Y Acad Sci; 2006 Jun; 1069():414-9. PubMed ID: 16855168
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular outcomes and tumour necrosis factor antagonists in chronic inflammatory rheumatic disease: a focus on rheumatoid arthritis.
Tocci G; Goletti D; Marino V; Matucci A; Milano GM; Cantini F; Scarpa R
Expert Opin Drug Saf; 2016 Dec; 15(sup1):55-61. PubMed ID: 27924645
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular Safety of Biologics and JAK Inhibitors in Patients with Rheumatoid Arthritis.
Kang EH; Liao KP; Kim SC
Curr Rheumatol Rep; 2018 May; 20(7):42. PubMed ID: 29846814
[TBL] [Abstract][Full Text] [Related]
16. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
[TBL] [Abstract][Full Text] [Related]
17. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
Li N; Betts KA; Messali AJ; Skup M; Garg V
Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087
[TBL] [Abstract][Full Text] [Related]
18. Effects of biologics on vascular function and atherosclerosis associated with rheumatoid arthritis.
Kerekes G; Soltész P; Dér H; Veres K; Szabó Z; Végvári A; Shoenfeld Y; Szekanecz Z
Ann N Y Acad Sci; 2009 Sep; 1173():814-21. PubMed ID: 19758233
[TBL] [Abstract][Full Text] [Related]
19. Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long-term infliximab therapy.
Dahlqvist SR; Engstrand S; Berglin E; Johnson O
Scand J Rheumatol; 2006; 35(2):107-11. PubMed ID: 16641043
[TBL] [Abstract][Full Text] [Related]
20. Biologics and cardiovascular events in inflammatory arthritis: a prospective national cohort study.
Lee JL; Sinnathurai P; Buchbinder R; Hill C; Lassere M; March L
Arthritis Res Ther; 2018 Aug; 20(1):171. PubMed ID: 30086795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]